Baird analyst Michael Ulz reiterated an Outperform rating and $40 price target on Paratek Pharmaceuticals (NASDAQ: PRTK) saying they are ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE